CMC(SH:603122) Sou Hu Cai Jing·2025-05-07 10:30Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - HeFu China's closing price on May 7 was 6.63 yuan, with a PE ratio of 182.87, marking a new low in 21 days, and a total market capitalization of 2.639 billion yuan [1] - The average PE ratio for the pharmaceutical commercial industry is 36.32, with a median of 27.46, positioning HeFu China at 26th place within the industry [1][2] Group 2 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of HeFu China involves international trade and after-sales service of in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - In the latest quarterly report for Q1 2025, HeFu China reported revenue of 176 million yuan, a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, representing a year-on-year decline of 184.13%, with a gross profit margin of 16.71% [1]